Proteomics

Dataset Information

0

Organ specific fibroblast-derived matrix as a tool for understanding breast cancer metastasis


ABSTRACT: Triple negative breast cancer has an extremely poor prognosis due to lack of available targeted treatments, especially for metastasis. Metastatic sites frequently include the lymph nodes and the lungs, and during the metastatic process, breast cancer cells must come into contact with the extracellular matrix (ECM) at every step. The ECM provides both structural support and biochemical cues, and cell-ECM interactions can lead to changes in to drug response. Here, we used fibroblast-derived ECM to perform high throughput drug screening of 4T1 breast cancer cells on metastatic organ ECM (lung) and we see that drug response differs to drug inhibition on plastic. The FDM that we are able to produce from different metastatic organs is abundant in, and contains a complex mixture of ECM proteins. We also show differences in ECM composition between the primary site and metastatic sites. Furthermore, we show that global kinase signalling of 4T1 cells on the ECM is relatively unchanged between organs, however we show large changes in signalling compared to plastic. Our study highlights the importance of context when testing drug response in vitro, showing that the consideration of the ECM is critically important.

INSTRUMENT(S): Orbitrap Fusion

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Fibroblast

SUBMITTER: Erwin Schoof  

LAB HEAD: Janine Erler

PROVIDER: PXD025786 | Pride | 2022-02-17

REPOSITORIES: Pride

altmetric image

Publications

Organ-Specific, Fibroblast-Derived Matrix as a Tool for Studying Breast Cancer Metastasis.

Jensen Adina R D ARD   Horton Edward R ER   Blicher Lene H LH   Pietras Elin J EJ   Steinhauer Cornelia C   Reuten Raphael R   Schoof Erwin M EM   Erler Janine T JT  

Cancers 20210702 13


During the metastatic process, breast cancer cells must come into contact with the extra-cellular matrix (ECM) at every step. The ECM provides both structural support and biochemical cues, and cell-ECM interactions can lead to changes in drug response. Here, we used fibroblast-derived ECM (FDM) to perform high throughput drug screening of 4T1 breast cancer cells on metastatic organ ECM (lung), and we see that drug response differs from treatment on plastic. The FDMs that we can produce from diff  ...[more]

Similar Datasets

2011-02-17 | E-GEOD-27354 | biostudies-arrayexpress
2019-01-02 | PXD010362 | Pride
2022-08-02 | E-MTAB-8503 | biostudies-arrayexpress
2022-10-05 | PXD036736 | Pride
2023-10-17 | E-MTAB-13432 | biostudies-arrayexpress
2009-03-07 | E-GEOD-11259 | biostudies-arrayexpress
2015-11-01 | E-GEOD-71926 | biostudies-arrayexpress
2023-03-06 | E-MTAB-11741 | biostudies-arrayexpress
2022-07-29 | GSE181102 | GEO
2010-06-08 | E-GEOD-21994 | biostudies-arrayexpress